Electroconvulsive therapy in Parkinson's disease: 30 month follow up.

Pridmore, Saxby; Pollard, Catherine

doi:10.1136/jnnp.60.6.693

Cited by 34 publications

(17 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During this review period, there have been 21 new reports of patients with PD undergoing ECT, [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]26,27,29,30 and four additional reports describing ECT and parkinsonian syndromes (totaling 25 reports). During this review period, there have been 21 new reports of patients with PD undergoing ECT, [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]26,27,29,30 and four additional reports describing ECT and parkinsonian syndromes (totaling 25 reports).…”

Section: Parkinson's Disease and Parkinsonian Syndromesmentioning

confidence: 99%

“…12,26 One of these 12 focused on the safety of ECT with organic brain disorders and made no comment on the outcome of movement disorders. 14,[19][20][21][22]30 One 14 focused on the incidence of delirium in PD patients receiving ECT, with no comment on the movement disorder. There were four prospective, open trials during this review period.…”

Section: Parkinson's Disease and Parkinsonian Syndromesmentioning

confidence: 99%

“…The second 26 described the effect of ECT on parkinsonian symptoms in 25 patients, with 14 responding positively. Three reports [20][21][22] described the same group of patients, one with acute treatment and two with longterm followup; the overall response rate was nine out of 13 patients. 14,[19][20][21][22]30 One 14 focused on the incidence of delirium in PD patients receiving ECT, with no comment on the movement disorder.…”

Section: Parkinson's Disease and Parkinsonian Syndromesmentioning

confidence: 99%

See 2 more Smart Citations

Electroconvulsive Therapy in Movement Disorders: An Update

Kennedy

Mittal²,

O'Jile³

2003

JNP

View full text Add to dashboard Cite

Electroconvulsive therapy (ECT) is a well-recognized treatment for psychiatric illness, primarily depressive disorders. Its use in patients with neurological illnesses is steadily increasing. Older reviews indicate that ECT may also benefit Parkinson's disease and similar movement disorders independent of its effects on comorbid psychiatric disorders. In this updated review, recent literature regarding ECT and movement disorders is summarized from 1990 to 2000. Considerable evidence indicates that ECT improves motor symptoms of Parkinson's disease in patients with and without mood disorders. A few case reports, ranging from one to six patients per disorder, suggest that ECT may ameliorate the motor symptoms of other movement disorders. ECT affects a variety of neurotransmitters that play a role in these diseases. Limitations of current reports are reviewed, and recommendations for further investigation are made.

show abstract

Section: Parkinson's Disease and Parkinsonian Syndromesmentioning

confidence: 99%

Section: Parkinson's Disease and Parkinsonian Syndromesmentioning

confidence: 99%

Section: Parkinson's Disease and Parkinsonian Syndromesmentioning

confidence: 99%

See 1 more Smart Citation

Electroconvulsive Therapy in Movement Disorders: An Update

Kennedy

Mittal²,

O'Jile³

2003

JNP

View full text Add to dashboard Cite

show abstract

“…74,75 Indeed, ECT has been tried as a treatment for motor symptoms in PD patients without depression, with apparent positive results, lasting from several weeks to months. [76][77][78] Looking at the limited number of studies, and their largely negative results, it is not surprising that 2 systematic reviews have concluded that there is insufficient evidence for the efficacy and safety of SSRIs and tricyclic antidepressants (TCAs) in the treatment of depression in PD, with the exception of a possible efficacy of nortriptyline. 79,80 The most important consequence of the high placeboresponse in the aforementioned double-blind studies is that studies that have not followed a placebo-controlled design will never provide evidence of a superior efficacy of antidepressant treatment.…”

Section: Treatmentmentioning

confidence: 99%

Depression in Parkinson’s Disease: Conceptual Issues and Clinical Challenges

Leentjens

2004

J Geriatr Psychiatry Neurol

127

View full text Add to dashboard Cite

Background: Depression frequently accompanies Parkinson’s disease (PD) and may have a negative impact on activities of daily living, cognitive performance, and quality of life. Because of the symptom overlap between the 2 disorders, it may be difficult to recognize depression in PD. Moreover, the partially shared pathophysiology may make it difficult to treat depressive symptoms without influencing motor or cognitive function. Objective: To review the current knowledge of the epidemiology, etiology, pathophysiology, and treatment of depression in patients with Parkinson’s disease. Method: Discussion of recent studies and relevant literature. Conclusion: Not only conceptually but also in terms of etiology, pathophysiology, and treatment, the relationship between PD and depression remains a challenge. There are still many questions to be answered. In the therapeutic domain, large, placebo-controlled trials are necessary to evaluate the efficacy of antidepressant treatment and allow the development of evidence-based guidelines. (J Geriatr Psychiatry Neurol 2004; 17:120-126)

show abstract

“…Die Nachhaltigkeit der Besserung der Parkinsonsymptomatik durch EKT scheint individuell sehr verschieden zu sein [55]. Einige Studien legen eine gute Wirksamkeit der M-EKT bei Morbus Parkinson nahe [56][57][58], in der Praxis wird dieses Therapieverfahren jedoch kaum eingesetzt. Vor allem die zunehmende Bedeutung der tiefen Hirnstimulation des Nucleus Subthalamicus bei fortgeschrittenem Morbus Parkinson relativiert den Einsatz der M-EKT in dieser Indikation [59].…”

Section: Langzeit-ekt Bei Morbus Parkinsonunclassified

Electroconvulsive therapy as continuation and maintenance therapy in psychiatric disorders and Parkinson’s disease

Willeit

Praschak-Rieder

Kasper

2003

Wien Klin Wochenschr

View full text Add to dashboard Cite

Electroconvulsive therapy is a reliable and safe option for patients with psychiatric disorders who are resistant or intolerant to medication as these patients usually respond quickly to this form of treatment. For clinicians, the management of these often severely ill patients is an important challenge given the high rate of relapse of these disorders. Maintenance electroconvulsive therapy is an interesting treatment option for these patients. Until now, only few controlled studies exist about the long-term outcome of this treatment in depressive disorders and other psychiatric disorders. Altogether, this form of outpatient prophylactic therapy has been found to be safe, well tolerated, and efficacious in relapse prevention. Moreover, it has been found to reduce hospitalization rates. Particularly in the elderly, and in patients who have been shown to be refractory to medication regimens, maintenance electroconvulsive therapy should be seriously considered as a means to reduce the risk of recurrence of illness. In Parkinson's disease maintenance electroconvulsive therapy is not widely established although its usefulness has been documented in numerous studies. First-line evidence data on incidence, dimensions and outcome of cognitive side effects under maintenance electroconvulsive therapy is still warranted.

show abstract

Electroconvulsive therapy in Parkinson's disease: 30 month follow up.

Cited by 34 publications

References 1 publication

Electroconvulsive Therapy in Movement Disorders: An Update

Electroconvulsive Therapy in Movement Disorders: An Update

Depression in Parkinson’s Disease: Conceptual Issues and Clinical Challenges

Electroconvulsive therapy as continuation and maintenance therapy in psychiatric disorders and Parkinson’s disease

Contact Info

Product

Resources

About